Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects
暂无分享,去创建一个
James M. Mountz | Charles M. Laymon | Ann D. Cohen | William E. Klunk | Chester A. Mathis | Julie C. Price | Howard J. Aizenstein | Eric McDade | J. Mountz | C. Laymon | W. Klunk | E. McDade | C. Mathis | J. Price | H. Aizenstein | A. Cohen | S. Boudhar | Zheng Zhang | Sanaa Boudhar | Zheng Zhang | J. Price | J. Price
[1] Amity E. Green,et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects , 2010, Neurobiology of Aging.
[2] J. Fleiss. Measuring nominal scale agreement among many raters. , 1971 .
[3] J. Mazziotta,et al. MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.
[4] Paul Maruff,et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.
[5] J. Fleiss,et al. A Re-analysis of the Reliability of Psychiatric Diagnosis , 1974, British Journal of Psychiatry.
[6] Ranjan Duara,et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.
[7] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[8] Alan A. Wilson,et al. A rapid one-step radiosynthesis of the β-amyloid imaging radiotracer N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole ([11C]-6-OH-BTA-1) , 2004 .
[9] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[10] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[11] Philippe Pibarot,et al. The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. , 2012, European heart journal.
[12] Keith A. Johnson,et al. Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.
[13] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[14] Mary Ann Moran,et al. Synthesis and Evaluation , 1986 .
[15] L. Ferrucci,et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB , 2010, Neurology.
[16] J. Trojanowski,et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. , 2011, Archives of neurology.
[17] First PET Study with a Benzothiazol Amyloidimaging Agent (PIB) in Alzheimer’s Disease Patients and Healthy Volunteers , 2004 .
[18] M. Viitanen,et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.
[19] B. Miller,et al. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease , 2012, Neurobiology of Aging.
[20] A. Feinstein,et al. High agreement but low kappa: II. Resolving the paradoxes. , 1990, Journal of clinical epidemiology.
[21] Lisa A. Weissfeld,et al. Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches , 2013, NeuroImage.
[22] Cindee M. Madison,et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.
[23] G. Linazasoro,et al. IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.
[24] W. Klunk,et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.
[25] Jacob Cohen. A Coefficient of Agreement for Nominal Scales , 1960 .
[26] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[27] H. Engler,et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.
[28] Nick C Fox,et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.
[29] Lisa A. Weissfeld,et al. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET , 2010, NeuroImage.
[30] J. Trojanowski,et al. Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.